文献速递胸部肿瘤

靶向桥粒胶蛋白-3的TLR-2激动剂CADI-05治疗晚期非小细胞肺癌的随机试验

A randomized trial of TLR-2 agonist CADI-05 targeting desmocollin-3 for advanced non-small-cell lung cancer.
PubMed 文献 · Ann Oncol · 2017-01-01

这项随机对照试验将晚期非小细胞肺癌患者分为顺铂-紫杉醇化疗组(112例)与顺铂-紫杉醇联合CADI-05的化免疫治疗组(109例),比较总生存。意向性分析显示两组无生存获益(208天对196天,风险比0.86,95%置信区间0.63-1.19,P=0.3804)。鳞癌亚组及完成4周期化疗者中化免疫治疗组生存改善。

要点

  • 意向性分析两组总生存无显著差异:208天对196天,风险比0.86,95%置信区间0.63-1.19,P=0.3804。
  • 鳞癌亚组化免疫治疗组中位生存改善127天,风险比0.55,95%置信区间0.32-0.95,P=0.046。
  • 完成计划4周期化疗者化免疫治疗组中位总生存改善66天(299天对233天),风险比0.64,95%置信区间0.41-0.98,P=0.04。

核心结论

  • 在晚期非小细胞肺癌患者中,顺铂-紫杉醇联合CADI-05未带来生存获益,但鳞癌亚组显示出生存优势。

研究设计与样本

  • 随机对照试验,纳入晚期非小细胞肺癌(IIIB或IV期)患者,化疗组112例,化免疫治疗组109例。

主要发现

  • 意向性分析显示两组总生存无显著差异:208天对196天,风险比0.86,95%置信区间0.63-1.19,P=0.3804。
  • 鳞癌亚组化免疫治疗组中位生存改善127天,风险比0.55,95%置信区间0.32-0.95,P=0.046。
  • 完成计划4周期化疗者化免疫治疗组中位总生存改善66天(299天对233天),风险比0.64,95%置信区间0.41-0.98,P=0.04。
  • 化免疫治疗组1年末生存改善17.48%。
  • 两组全身不良事件相同。

关键数值与推荐

  • CADI-05于化疗前一周及每周期第8天和第15天给药,此后每月给药,持续12个月或至疾病进展。
  • 基线、2周期和4周期结束时行计算机断层扫描,由独立放射科医师按实体瘤疗效评价标准评估缓解率。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Randomized controlled trial to evaluate synergy between taxane plus platinum chemotherapy and CADI-05, a Toll like receptor-2 agonist targeting desmocollin-3 as a first-line therapy in advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Patients with advanced NSCLC (stage IIIB or IV) were randomized to cisplatin-paclitaxel (chemotherapy group, N = 112) or cisplatin-paclitaxel plus CADI-05 (chemoimmunotherapy group, N = 109). CADI-05 was administered a week before chemotherapy and on days 8 and 15 of each cycle and every month subsequently for 12 months or disease progression. Overall survival was compared using a log-rank test. Computed tomography was carried out at baseline, end of two cycles and four cycles. Response rate was evaluated using Response Evaluation Criteria in Solid Tumors criteria by an independent radiologist. RESULTS: As per intention-to-treat analysis, no survival benefit was observed between two groups [208 versus 196 days; hazard ratio, 0.86; 95% confidence interval (CI) 0.63-1.19; P = 0.3804]. In a subgroup analysis, improvement in median survival by 127 days was observed in squamous NSCC with chemoimmunotherapy (hazard ratio, 0.55; 95% CI 0.32-0.95; P = 0.046). In patients receiving planned four cycles of chemotherapy, there was improved median overall survival by 66 days (299 versus 233 days; hazard ratio, 0.64; 95% CI 0.41 to 0.98; P = 0.04) in the chemoimmunotherapy group compared with the chemotherapy group. This was associated with the improved survival by 17.48% at the end of 1 year, in the chemoimmunotherapy group. Systemic adverse events were identical in both the groups. CONCLUSION: There was no survival benefit with the addition of CADI-05 to the combination of cisplatin-paclitaxel in patients with advanced NSCLC; however, the squamous cell subset did demonstrate a survival advantage.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Belani CP, Chakraborty BC, Modi RI, et al. A randomized trial of TLR-2 agonist CADI-05 targeting desmocollin-3 for advanced non-small-cell lung cancer. Ann Oncol. 2017. PMID: 27831503. doi:10.1093/annonc/mdw608

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。